Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

PETTA, Salvatore
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.056
EU - Europa 12.654
AS - Asia 12.139
SA - Sud America 2.020
AF - Africa 336
OC - Oceania 46
Continente sconosciuto - Info sul continente non disponibili 23
Totale 53.274
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.572
SG - Singapore 4.538
RU - Federazione Russa 3.444
CN - Cina 2.948
IT - Italia 2.877
BR - Brasile 1.595
DE - Germania 1.538
HK - Hong Kong 1.205
FI - Finlandia 1.196
VN - Vietnam 1.060
PL - Polonia 782
BD - Bangladesh 643
FR - Francia 568
GB - Regno Unito 510
UA - Ucraina 429
IE - Irlanda 395
JP - Giappone 378
IN - India 307
CA - Canada 250
KR - Corea 249
AR - Argentina 163
SE - Svezia 159
NL - Olanda 153
RO - Romania 136
TR - Turchia 134
AT - Austria 112
MX - Messico 110
IQ - Iraq 108
BE - Belgio 81
ZA - Sudafrica 73
ES - Italia 72
CI - Costa d'Avorio 64
ID - Indonesia 64
SA - Arabia Saudita 57
EC - Ecuador 54
CO - Colombia 52
PK - Pakistan 47
UZ - Uzbekistan 46
PH - Filippine 44
IR - Iran 42
AU - Australia 40
MA - Marocco 38
MY - Malesia 38
EG - Egitto 36
VE - Venezuela 36
JM - Giamaica 35
PY - Paraguay 34
CL - Cile 33
KE - Kenya 33
GR - Grecia 29
DK - Danimarca 27
AE - Emirati Arabi Uniti 24
CH - Svizzera 24
NP - Nepal 22
TN - Tunisia 22
AZ - Azerbaigian 21
JO - Giordania 20
BG - Bulgaria 19
CZ - Repubblica Ceca 19
PE - Perù 19
DZ - Algeria 18
CR - Costa Rica 17
LT - Lituania 17
TH - Thailandia 17
AL - Albania 15
BO - Bolivia 15
KZ - Kazakistan 15
LB - Libano 15
IL - Israele 14
KG - Kirghizistan 14
UY - Uruguay 14
HN - Honduras 11
NI - Nicaragua 11
TT - Trinidad e Tobago 11
EU - Europa 10
GE - Georgia 10
OM - Oman 10
BY - Bielorussia 9
NG - Nigeria 9
SV - El Salvador 8
DO - Repubblica Dominicana 7
MD - Moldavia 7
MM - Myanmar 7
QA - Qatar 7
SN - Senegal 7
XK - ???statistics.table.value.countryCode.XK??? 7
ET - Etiopia 6
GT - Guatemala 6
NZ - Nuova Zelanda 6
A2 - ???statistics.table.value.countryCode.A2??? 5
BN - Brunei Darussalam 5
MO - Macao, regione amministrativa speciale della Cina 5
PA - Panama 5
PS - Palestinian Territory 5
RS - Serbia 5
SD - Sudan 5
TG - Togo 5
TW - Taiwan 5
BA - Bosnia-Erzegovina 4
CY - Cipro 4
Totale 53.197
Salva come PNG Salva come JPEG
Città #
Singapore 3.268
Fairfield 3.120
Ashburn 3.060
San Jose 1.584
Woodbridge 1.498
Chandler 1.351
Seattle 1.248
Houston 1.235
Wilmington 1.167
Hong Kong 1.135
Cambridge 1.080
Ann Arbor 715
Zgierz 690
Palermo 644
Moscow 593
Beijing 455
Medford 441
Los Angeles 421
Helsinki 411
Dublin 391
Des Moines 390
New York 383
Ho Chi Minh City 369
Secaucus 353
Altamura 340
Tokyo 340
Santa Clara 337
Lauterbourg 329
Cologne 327
Council Bluffs 310
Princeton 281
Dallas 278
Hanoi 261
Nanjing 258
Lawrence 256
Frankfurt am Main 221
Jacksonville 221
Boardman 209
Hefei 189
San Diego 168
Chicago 165
Buffalo 151
Rome 147
The Dalles 135
São Paulo 132
Milan 130
Nuremberg 104
Jinan 100
London 98
Shenyang 94
Ludwigshafen am Rhein 91
Orem 90
Dearborn 86
Changsha 81
Tulsa 76
Nanchang 74
Phoenix 73
Tianjin 72
Hebei 69
Lappeenranta 67
Warsaw 66
Abidjan 64
Atlanta 64
Zhengzhou 64
Chennai 62
Jiaxing 62
Brussels 58
Amsterdam 57
Columbus 57
Shanghai 56
Denver 55
Brooklyn 54
Guangzhou 51
Izmir 51
Hangzhou 47
Paris 47
Haiphong 45
Manchester 44
Munich 44
Saint Petersburg 44
San Paolo di Civitate 44
Seongnam 44
Johannesburg 43
Montreal 43
Baghdad 42
Da Nang 42
Mumbai 42
Redwood City 41
Rio de Janeiro 40
Seoul 40
Vienna 40
Naples 37
Toronto 37
Belo Horizonte 36
Central 36
Tashkent 36
Ningbo 35
Boston 32
Falls Church 32
Brasília 31
Totale 34.227
Salva come PNG Salva come JPEG
Nome #
"Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV" 1.272
Diet, Weight Loss, and Liver Health in NAFLD: Pathophysiology, Evidence and Practice 551
Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis 396
The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease 345
HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals 330
Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease 325
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030 325
Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis 318
Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C. 313
Transmembrane 6 Superfamily Member 2 Gene Variant Disentangles Nonalcoholic Steatohepatitis From Cardiovascular Disease 311
Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. 309
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial 308
The presence of white matter lesions is associated with the fibrosis severity of nonalcoholic fatty liver disease 303
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease 298
A "systems medicine" approach to the study of non-alcoholic fatty liver disease 290
L’insulino-resistenza è il principale fattore indipendente correlato con l’aumentato rischio metabolico nelle donne affette da PCOS 288
Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. 281
Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients 280
Obstructive Sleep Apnea Is Associated with Liver Damage and Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease 273
Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis 272
Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation 269
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 265
751 RETINOL-BINDING PROTEIN 4 (RBP4): A NEW MARKER OF G1 HCV-INDUCED STEATOSIS 263
Antidiabetic drugs in NAFLD: The accomplishment of two goals at once? 262
Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women 259
Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS 259
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions 259
PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease 257
The cheating liver: imaging of focal steatosis and fatty sparing 257
Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C 256
The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. 255
The Hepatic Expression of Vitamin D Receptor is Inversely Associated with the Severity of Liver Damage in Genotype 1 Chronic Hepatitis C Patients. 253
Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection 251
MAFLD: a multisystem disease 250
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis 250
Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. 249
Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations. 248
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 248
Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study 248
High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis 246
Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection 245
Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver 243
The course of oesophagogastric varices in patients with cirrhosis after DAA-induced HCV clearance 243
MERTK rs4374383 polymorphism affects the severity of fibrosis in nonalcoholic fatty liver disease 240
Cost-Effectiveness of Boceprevir or Telaprevir for Untreated Patients with Genotype 1 Chronic Hepatitis C 237
Metabolic Factors and Chronic Hepatitis C: A Complex Interplay 237
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 235
Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. 233
Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients 233
Retinol-binding protein 4 (RBP4) : a new marker of G1 HCV-induced steatosis 230
Association of vitamin D serum levels and its common genetic determinants with severity of liver fibrosis in genotype 1 chronic hepatitis C patients 230
Fibrosis Evaluation by Transient Elastography in Patients With Long-Term Sustained HCV Clearance 229
Genetic background in nonalcoholic fatty liver disease: A comprehensive review 228
Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease 228
LIPIDOMICS OF FATTY LIVER IN NAFLD AND HCV INFECTION: LIVER SPHYNGOLIPIDS AND FATTY ACIDS 227
High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C 223
A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease 222
Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C 221
qFIBS: A Novel Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis 221
STORIA NATURALE DELLA CIRROSI EPATICA 220
Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis C virus genotype 1. 220
TM6SF2 rs58542926 is not associated with steatosis and fibrosis in largecohort of patients with genotype 1 chronic hepatitis C 217
Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. 215
Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort 215
Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis. 211
The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. 209
Serum BLYS/BAFF levels in acute hepatitis C predict clinical outcome 208
Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C 203
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 200
Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies 199
Liver stiffness quantification in patients with non-alcoholic steatohepatitis: comparison of shear wave elastography and transient elastography with liver biopsy correlation 199
AISF position paper on HCV in immunocompromised patients 198
Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C 197
Statin use and non-alcoholic steatohepatitis in at risk individuals 197
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents 197
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 197
Methylenetetrahydrofolate reductase homozygosis and low-density lipoproteins in patients with genotype 1 chronic hepatitis C 196
The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent 196
Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? the REAL Experience 196
Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma 196
Development and Validation of Hepamet Fibrosis Scoring System A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis 195
Metformina e pioglitazone in soggetti affetti da diabete mellito tipo 2 con steatosi epatica 194
Hepatic expression of cyclooxygenase-2 in non alcoholic fatty liver disease 193
Fibronectin type III domain-containing protein 5 rs3480 A>G polymorphism, irisin, and liver fibrosis in patients with Nonalcoholic fatty liver disease 193
Serum γ-glutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases. 192
Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients with Nonalcoholic Fatty Liver Disease 192
FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage 192
Cardiovascular diseases and HCV infection: a simple association or more? 191
Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values 191
Pharmacological therapy of non-alcoholic fatty liver disease: What drugs are available now and future perspectives 191
Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. 190
Hyperuricemia in non-alcoholic fatty liver disease: authors' reply. 189
Application of guidelines for the management of nonalcoholic fatty liver disease in three prospective cohorts of HIV-monoinfected patients 188
Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population 188
Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. 187
Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis 186
Point-of-care HCV RNA testing in the setting of DAA therapy: HCV-FiS (HEpatitis C Virus Fingerstick Study) 186
Optimal therapy in hepatitis C virus genotypes 2 and 3 patients. 185
MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals 185
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 185
Totale 24.976
Salva come PNG Salva come JPEG
Categoria #
all - tutte 193.743
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 193.743
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.291 165 562 119 92 75 150 145 348 392 387 248 608
2022/20234.459 497 947 80 427 416 650 315 330 462 44 208 83
2023/20242.004 79 291 113 138 169 515 239 108 31 63 57 201
2024/20255.944 166 311 465 551 184 277 400 354 422 698 865 1.251
2025/202623.239 1.288 958 1.360 2.116 2.229 3.248 3.298 2.358 1.975 2.079 1.261 1.069
2026/2027477 477 0 0 0 0 0 0 0 0 0 0 0
Totale 55.072